We use polymer-based technology that makes new formulation development simple, scalable and affordable.

The OCL-Platform forms hydrogels and consists of bio-erodable polymers, that are safe, easy to scale-up and easy to formulate with very different types of drugs:

  • small molecule drugs, peptides, hormones, proteins and anti-bodies
  • from poorly soluble to highly soluble
  • with Molecular weights from 100D to 150kD
  • and loading from 0.01% up to 5% drug weight/volume

Last but not Least: the raw materials are all readily available, off the shelf at Pharma grade. Our formula has several base patents pending while we prepare for new patents in the coming years. 

The OCL-formulations are easily injected through thin needles (up to 30G) or catheters (up to 1 meter) in any location. Upon injection, the formulation rapidly forms a stable matrix, resulting in the localized drug depot ‘in situ – in seconds’. As the depot degrades, the stored drugs are slowly released into the surrounding tumor.

The OCL-platform has been developed & optimized for localized and slow release of different drugs in tumors at different locations, using different methods of injection.

The depots are imageable on MRI, CT and Ultra Sound.

    OncoLize will develop the OCL-platform for all types of tumor diseases. We have selected a range of suitable oncology drugs, both generic and novel.

    These are formulated by OncoLize as oncology products for slow, localized delivery in solid tumors. Together with our partners we will develop a pipeline of products for some of the most deadly tumor diseases.

    Technology licenses for external development can be made available for selected Product-Market Combinations.